Published in Prostate on May 15, 2010
Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clin Cancer Res (2015) 1.80
Retracted Association of Polymorphism rs198977 in Human Kallikrein-2 Gene (KLK2) with Susceptibility of Prostate Cancer: A Meta-Analysis. PLoS One (2013) 1.37
Expression of kallikrein-related peptidase 4 in dental and non-dental tissues. Eur J Oral Sci (2011) 1.07
Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: the ABRF glycoprotein research multi-institutional study 2012. Mol Cell Proteomics (2013) 1.03
Identification and function of proteolysis regulators in seminal fluid. Mol Reprod Dev (2012) 1.02
Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. Prostate (2011) 0.97
Genome-wide association study identifies loci at ATF7IP and KLK2 associated with percentage of circulating free PSA. Neoplasia (2013) 0.79
A Single Glycan at the 99-Loop of Human Kallikrein-related Peptidase 2 Regulates Activation and Enzymatic Activity. J Biol Chem (2015) 0.76
KLK-targeted Therapies for Prostate Cancer. EJIFCC (2014) 0.75
Genome-wide association study identifies genetic determinants of urine PCA3 levels in men. Neoplasia (2013) 0.75
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. J Natl Cancer Inst (2017) 0.75
Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell (2003) 6.38
Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol (1999) 4.85
Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res (2000) 3.71
A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology (2000) 2.69
Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res (2003) 1.60
Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate (2007) 1.55
Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res (1997) 1.51
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol (2008) 1.47
A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst (2007) 1.41
Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim Biophys Acta (2007) 1.40
Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis. J Cell Biochem (2005) 1.25
Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun (1997) 1.22
Activation profiles and regulatory cascades of the human kallikrein-related peptidases. J Biol Chem (2007) 1.19
Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate (2001) 1.17
Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology (1999) 1.16
Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem (1997) 1.06
Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res (1997) 1.04
Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade. Possible function in seminal plasma and skin. J Biol Chem (2007) 0.99
In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts. Prostate (2000) 0.97
The kallikrein world: an update on the human tissue kallikreins. Biol Chem (2006) 0.94
Evolution of kallikrein-related peptidases in mammals and identification of a genetic locus encoding potential regulatory inhibitors. Biol Chem (2006) 0.90
Seminal fluid characterization for male fertility and prostate cancer: kallikrein-related serine proteases and whole proteome approaches. Semin Thromb Hemost (2007) 0.90
Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells. Prostate Cancer Prostatic Dis (1999) 0.86
Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer. Mol Cancer Ther (2004) 0.85
Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing. Prostate (2001) 0.83
Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. Proc Natl Acad Sci U S A (1997) 0.83
Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. Biochemistry (2001) 0.82
Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells. Prostate (2000) 0.81
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Prostate cancer. N Engl J Med (2003) 5.91
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18
Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat Med (2009) 3.17
Precise segmental renal artery clamping under the guidance of dual-source computed tomography angiography during laparoscopic partial nephrectomy. Eur Urol (2012) 2.95
Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res (2004) 2.84
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res (2002) 2.84
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget (2011) 2.80
Epidemiology of inflammation and prostate cancer. J Urol (2004) 2.76
Loss of inhibitory interneurons in the dorsal spinal cord and elevated itch in Bhlhb5 mutant mice. Neuron (2010) 2.69
Prostate cancer and inflammation: the evidence. Histopathology (2012) 2.60
A complete sequence of the T. tengcongensis genome. Genome Res (2002) 2.60
A history of prostate cancer treatment. Nat Rev Cancer (2002) 2.46
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis (2004) 2.33
The role of inflammation in the pathogenesis of prostate cancer. J Urol (2004) 2.29
The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res (2008) 2.29
Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res (2002) 2.24
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw (2011) 2.24
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17
Novel as1 and as2 defects in leaf adaxial-abaxial polarity reveal the requirement for ASYMMETRIC LEAVES1 and 2 and ERECTA functions in specifying leaf adaxial identity. Development (2003) 2.17
Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab (2003) 2.16
DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res (2008) 2.08
Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia (2008) 2.07
A "dock, lock, and latch" structural model for a staphylococcal adhesin binding to fibrinogen. Cell (2003) 2.06
A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate (2008) 2.04
Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res (2006) 2.02
Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res (2006) 2.02
Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A (2009) 2.02
Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 2.00
Safety and long-term efficacy of endovascular treatment of small posterior communicating artery aneurysms by coiling with or without stent: a single center retrospective study. Clin Neurol Neurosurg (2013) 1.97
Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am J Pathol (2002) 1.95
XMRV: a new virus in prostate cancer? Cancer Res (2010) 1.95
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther (2004) 1.90
MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine. Cancer Biol Ther (2004) 1.82
Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA). Cancer Biol Ther (2004) 1.82
Munc18-1 binding to the neuronal SNARE complex controls synaptic vesicle priming. J Cell Biol (2009) 1.80
Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem (2005) 1.79
A 'Collagen Hug' model for Staphylococcus aureus CNA binding to collagen. EMBO J (2005) 1.78
Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol (2011) 1.76
Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res (2006) 1.76
Chronic tumor necrosis factor-alpha inhibition enhances NO modulation of vascular function in estrogen-deficient rats. Hypertension (2005) 1.75
Cyclooxygenases in cancer: progress and perspective. Cancer Lett (2004) 1.74
Autophagy regulates phagocytosis by modulating the expression of scavenger receptors. Immunity (2013) 1.73
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst (2003) 1.73
Lbx1 and Tlx3 are opposing switches in determining GABAergic versus glutamatergic transmitter phenotypes. Nat Neurosci (2005) 1.73
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol (2008) 1.71
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
US-guided percutaneous microwave coagulation of small breast cancers: a clinical study. Radiology (2012) 1.66
Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res (2006) 1.65
MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One (2010) 1.65
Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol (2003) 1.65
A family of putative MSCRAMMs from Enterococcus faecalis. Microbiology (2004) 1.63
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014) 1.61
Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci U S A (2006) 1.61
Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate (2003) 1.60
Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res (2006) 1.60
Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev (2004) 1.60
A novel role of myosin VI in human prostate cancer. Am J Pathol (2006) 1.59
Voice F0 responses to pitch-shifted voice feedback during English speech. J Acoust Soc Am (2007) 1.58
Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol (2011) 1.58
GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem (2004) 1.58
Tumor necrosis factor-alpha and vascular angiotensin II in estrogen-deficient rats. Hypertension (2006) 1.57
In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. J Cell Biochem (2004) 1.57
A self-assembled DNA nanostructure-amplified quartz crystal microbalance with dissipation biosensing platform for nucleic acids. Chem Commun (Camb) (2012) 1.56
Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. Int J Cancer (2009) 1.56
The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer. Cancer Biol Ther (2005) 1.56
Epigenetic alterations in human prostate cancers. Endocrinology (2009) 1.55
Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate (2007) 1.55
PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate (2006) 1.55
Practical methods for tissue microarray construction. Methods Mol Med (2005) 1.54
ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol (2011) 1.54
MYC and Prostate Cancer. Genes Cancer (2010) 1.54
Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget (2011) 1.52
Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res (2004) 1.50
Telomere length as a risk factor for hereditary prostate cancer. Prostate (2013) 1.50